Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial

A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combinati...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antiviral therapy 2018-01, Vol.23 (3), p.219-227
Hauptverfasser:	Lee, Sae Hwan, Cheon, Gab Jin, Kim, Hong Soo, Kim, Sang Gyune, Kim, Young Seok, Jeong, Soung Won, Jang, Jae Young, Kim, Boo Sung, Jun, Baek Gyu, Don Kim, Young, Jun, Dae Won, Sohn, Joo Hyun, Kim, Tae Yeob, Lee, Byung Seok
Format:	Artikel
Sprache:	eng
Schlagworte:	Adefovir Adefovir dipivoxil Deoxyribonucleic acid DNA Hepatitis Hepatitis B e antigen Interferon Lamivudine Mutation Nucleoside analogs Tenofovir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!